{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T07:02:23Z","timestamp":1761894143003},"reference-count":16,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2005,6,15]],"date-time":"2005-06-15T00:00:00Z","timestamp":1118793600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Osteoporos Int"],"published-print":{"date-parts":[[2005,12]]},"DOI":"10.1007\/s00198-005-1911-7","type":"journal-article","created":{"date-parts":[[2005,6,14]],"date-time":"2005-06-14T10:26:59Z","timestamp":1118744819000},"page":"1727-1730","source":"Crossref","is-referenced-by-count":18,"title":["Absorption of the oral bisphosphonate alendronate in osteoporotic patients with Crohn\u2019s disease"],"prefix":"10.1007","volume":"16","author":[{"given":"Serge C. L. M.","family":"Cremers","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruud","family":"van Hogezand","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Denise","family":"B\u00e4nffer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jan","family":"den Hartigh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pieter","family":"Vermeij","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Socrates E.","family":"Papapoulos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Neveen A. T.","family":"Hamdy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2005,6,15]]},"reference":[{"key":"1911_CR1","first-page":"1157","volume":"92","author":"Bisschoff","year":"1997","unstructured":"Bisschoff SC, Herrmann A, Goeke M, Manns MP, von zur Muehlen A, Brabant G (1997) Altered bone metabolism in inflammatory bowel disease. Am J Gastroenterol 92:1157\u20131163","journal-title":"Am J Gastroenterol"},{"key":"1911_CR2","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.1001\/jama.280.24.2077","volume":"280","author":"Cummings","year":"1998","unstructured":"Cummings SR, Black DM, Thompson DE, Applegate WB, Barrett-Connor E, Musliner TA et al (1998) Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures\u2014Results from the fracture intervention trial. JAMA 280:2077\u20132082","journal-title":"JAMA"},{"key":"1911_CR3","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1056\/NEJM199807303390502","volume":"339","author":"Saag","year":"1998","unstructured":"Saag KG, Emkey R, Schnitzer TJ, Brown JP, Hawkins F, Goemaere S et al (1998) Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. N Engl J Med 339:292\u2013299","journal-title":"N Engl J Med"},{"key":"1911_CR4","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1056\/NEJM200008313430902","volume":"604","author":"Orwoll","year":"2000","unstructured":"Orwoll E, Ettinger M, Weiss S, Miller P, Kendler D, Graham J et al (2000) Alendronate for the treatment of osteoporosis in men. N Engl J Med 604:604\u2013610","journal-title":"N Engl J Med"},{"key":"1911_CR5","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/0009-9236(95)90245-7","volume":"58","author":"Gertz","year":"1995","unstructured":"Gertz BJ, Holland SD, Kline WF, Matuszewski BK, Freeman A, Quan H et al (1995) Studies on the oral bioavailability of alendronate. Clin Pharmacol Ther 58:288-298","journal-title":"Clin Pharmacol Ther"},{"key":"1911_CR6","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1023\/A:1011910517200","volume":"15","author":"Mitchell","year":"1998","unstructured":"Mitchell DY, Eusebio RA, Dunlap LE, Pallone KA, Nesbitt JD, Russell DA et al (1998) Risedronate gastrointestinal absorption is independent of site and rate of administration. Pharm Res 15:228\u2013232","journal-title":"Pharm Res"},{"key":"1911_CR7","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/8756-3282(95)00445-9","volume":"18","author":"Lin","year":"1996","unstructured":"Lin JH (1996) Bisphosphonates: A review of their pharmacokinetic properties. Bone 18:75\u201385","journal-title":"Bone"},{"key":"1911_CR8","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1053\/gast.2000.17841","volume":"119","author":"Leder","year":"2000","unstructured":"Leder BZ, Kronenberg HM (2000) Gastroenterologists and choosing the right bisphosphonate. Gastroenterology 119:866\u2013869","journal-title":"Gastroenterology"},{"key":"1911_CR9","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1053\/gast.2000.16518","volume":"119","author":"Haderslev","year":"2000","unstructured":"Haderslev KV, Tjellesen L, Sorensen HA, Staun M (2000) Alendronate increases lumbar spine bone mineral density in patients with Crohn\u2019s disease. Gastroenterology 119:639\u2013646","journal-title":"Gastroenterology"},{"key":"1911_CR10","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/S0378-4347(97)00507-0","volume":"705","author":"Sparidans","year":"1998","unstructured":"Sparidans RW, den Hartigh J, Beijnen JH, Vermeij P (1998) Semi-automatic liquid chromatographic analysis of pamidronate in serum and citrate plasma after derivatization with 1-naphthylisothiocyanate. J Chromatogr B Biomed Sci Appl 705:331\u2013339","journal-title":"J Chromatogr B Biomed Sci Appl"},{"key":"1911_CR11","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/S0378-4347(99)00196-6","volume":"730","author":"Sparidans","year":"1999","unstructured":"Sparidans RW, den Hartigh J, Cremers SCLM, Beijnen JH, Vermeij P (1999) Semi-automatic liquid chromatographic analysis of pamidronate in urine after derivatization with 1-naphthylisothiocyanate. J Chromatogr B Biomed Sci Appl 730:95\u201399","journal-title":"J Chromatogr B Biomed Sci Appl"},{"key":"1911_CR12","doi-asserted-by":"crossref","first-page":"431","DOI":"10.2165\/00003088-199121060-00004","volume":"21","author":"Gubbins","year":"1991","unstructured":"Gubbins PO, Bertch KE (1991) Drug absorption in gastrointestinal disease and surgery. Clin Pharmacokinet 21:431\u2013447","journal-title":"Clin Pharmacokinet"},{"key":"1911_CR13","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1007\/s00228-001-0411-8","volume":"57","author":"Cremers","year":"2002","unstructured":"Cremers SCLM, Sparidans RW, den Hartigh J, Hamdy NAT, Vermeij P, Papapoulos SE (2002) A pharmacokinetic and pharmacodynamic model for intravenous bisphosphonate (pamidronate) in osteoporosis. Eur J Clin Pharmacol 57:883\u2013890","journal-title":"Eur J Clin Pharmacol"},{"key":"1911_CR14","doi-asserted-by":"crossref","first-page":"253","DOI":"10.7326\/0003-4819-128-4-199802150-00001","volume":"128","author":"McClung","year":"1998","unstructured":"McClung M, Clemmesen B, Daifotis A, Gilchrist NL, Eisman J, Weinstein RS et al (1998) Alendronate prevents postmenopausal bone loss in women without osteoporosis\u2014A double-blind, randomized, controlled trial. Ann Intern Med 128:253\u2013261","journal-title":"Ann Intern Med"},{"key":"1911_CR15","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/S8756-3282(99)00087-3","volume":"24","author":"Garnero","year":"1999","unstructured":"Garnero P, Darte C, Delmas PD (1999) A model to monitor the efficacy of alendronate treatment in women with osteoporosis using a biochemical marker of bone turnover. Bone 24:603\u2013609","journal-title":"Bone"},{"key":"1911_CR16","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1002\/1529-0131(200101)44:1<202::AID-ANR27>3.0.CO;2-W","volume":"44","author":"Adachi","year":"2001","unstructured":"Adachi JD, Saag KG, Delmas PD et al (2001)Two-year effects of alendronate on bone mineral density and vertebral fracture in patients receiving glucocorticoids: a randomized, double-blind, placebo-controlled extension trial. Arthritis Rheum 44:202\u201311","journal-title":"Arthritis Rheum"}],"container-title":["Osteoporosis International"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-005-1911-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00198-005-1911-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-005-1911-7","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,23]],"date-time":"2019-05-23T15:03:56Z","timestamp":1558623836000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00198-005-1911-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,6,15]]},"references-count":16,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2005,12]]}},"alternative-id":["1911"],"URL":"https:\/\/doi.org\/10.1007\/s00198-005-1911-7","relation":{},"ISSN":["0937-941X","1433-2965"],"issn-type":[{"value":"0937-941X","type":"print"},{"value":"1433-2965","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,6,15]]}}}